Treatment with glatiramer acetate induces specific IgG4 antibodies in multiple sclerosis patients

被引:48
|
作者
Farina, C
Vargas, V
Heydari, N
Kümpfel, T
Meinl, E
Hohlfeld, R
机构
[1] Max Planck Inst Neurobiol, Dept Neuroimmunol, D-82152 Martinsried, Germany
[2] Univ Munich, Inst Clin Neuroimmunol, D-81366 Munich, Germany
关键词
multiple sclerosis; auto immunity; TH2-lymphocytes;
D O I
10.1016/S0165-5728(01)00490-8
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We analysed the humoral immune response to glatiramer acetate (GA, Copaxone) in 20 multiple sclerosis patients treated with GA, 20 patients not treated with GA and 20 normal control subjects. Using an ELISA for detection of total GA-reactive immunoglobulins (all isotypes), all treated patients but also 3/20 untreated and 8/20 healthy subjects scored positive at 1:20 plasma dilutions. At higher dilutions, 5/20 treated patients and two healthy donors had relatively high levels of anti-GA antibodies. Isotype and IgG subclass analysis revealed that the two antibody-positive normal subjects had IgM and small titers of IgG1 or IgG2 antibodies. In contrast, 18 of 20 GA-treated patients, had low but significant titers of GA-reactive IgG4 antibodies. This finding is consistent with the previously described GA-mediated induction of T-helper 2 (TH2)-like regulatory T cells. (C) 2002 Elsevier Science B.V All tights reserved.
引用
收藏
页码:188 / 192
页数:5
相关论文
共 50 条
  • [1] During 3 years treatment of primary progressive multiple sclerosis with glatiramer acetate, specific antibodies switch from IgG1 to IgG4
    Basile, Erika
    Gibbs, Ebrima
    Aziz, Tariq
    Oger, Joel
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 177 (1-2) : 161 - 166
  • [2] Long-term treatment with Glatiramer Acetate induces specific antibodies in treated MS patients; they start as IgG1 but are IgG4 in the long term
    Basile, E
    Gibbs, E
    Aziz, T
    Oger, J
    MULTIPLE SCLEROSIS, 2005, 11 : S162 - S163
  • [3] A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced by glatiramer acetate in relapsing-remitting multiple sclerosis patients
    Avila, Sandra
    De Jesus Guerrero-Garcia, Jose
    Becerril-Villanueva, Enrique
    Perez-Sanchez, Gilberto
    Pavon, Lenin
    Rojas-Mayorquin, Argelia E.
    Alberto Mireles-Ramirez, Mario
    Francisco Munoz-Vallee, Jose
    Vallejo-Castillo, Luis
    Medina-Rivero, Emilio
    Ortuno-Sahagun, Daniel
    Mayra Perez-Tapia, Sonia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 34 : 92 - 99
  • [4] Glatiramer acetate in the treatment of multiple sclerosis
    Miller, AE
    NEUROLOGIC CLINICS, 2005, 23 (01) : 215 - +
  • [5] Glatiramer acetate for the treatment of multiple sclerosis
    Wolinsky, JS
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (04) : 875 - 891
  • [6] Long-term treatment of multiple sclerosis patients with glatiramer acetate: clinical efficacy and anti-glatiramer acetate antibodies profile
    Teitelbaum, D.
    Brenner, T.
    Abramsky, O.
    Sicsic, C.
    Arnon, R.
    Karussis, D.
    MULTIPLE SCLEROSIS, 2006, 12 : S98 - S99
  • [7] Lymphadenopathy in patients with multiple sclerosis undergoing treatment with glatiramer acetate
    Windhagen, A
    Maniak, S
    Marckmann, S
    Wilkening, A
    Lindert, RB
    Heidenreich, F
    Blasczyk, R
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 70 (03): : 415 - 416
  • [8] Monitoring Glatiramer Acetate treatment in multiple sclerosis
    Farina, C
    Hohlfeld, R
    NEUROLOGY, 2002, 58 (07) : A246 - A246
  • [9] The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment
    Messina, Silvia
    Patti, Francesco
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (10) : 1349 - 1359
  • [10] Antibodies to glatiramer acetate in long-term treated multiple sclerosis patients
    Teitelbaum, D
    Arnon, R
    Karussis, D
    Abramsky, O
    Brenner, T
    MULTIPLE SCLEROSIS, 2005, 11 : S163 - S163